Filing Details

Accession Number:
0001209191-18-058086
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-11-13 09:17:53
Reporting Period:
2018-11-09
Accepted Time:
2018-11-13 09:17:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1419600 Flexion Therapeutics Inc FLXN Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1597407 D. Michael Clayman C/O Flexion Therapeutics, Inc.
10 Mall Road, Suite 301
Burlington MA 01803
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-06-27 554 $0.00 83,295 No 5 G Direct
Common Stock Disposition 2018-02-27 10,562 $0.00 72,733 No 5 G Direct
Common Stock Disposition 2018-10-11 8,567 $0.00 64,166 No 5 G Direct
Common Stock Acquisiton 2018-11-09 5,000 $17.10 69,166 No 4 P Direct
Common Stock Acquisiton 2018-06-27 554 $0.00 294,937 No 5 G Indirect By the Michael D.Clayman 2006 Revocable Trust
Common Stock Acquisiton 2018-02-27 10,562 $0.00 305,499 No 5 G Indirect By the Michael D.Clayman 2006 Revocable Trust
Common Stock Acquisiton 2018-10-11 8,567 $0.00 314,066 No 5 G Indirect By the Michael D.Clayman 2006 Revocable Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 5 G Direct
No 5 G Direct
No 5 G Direct
No 4 P Direct
No 5 G Indirect By the Michael D.Clayman 2006 Revocable Trust
No 5 G Indirect By the Michael D.Clayman 2006 Revocable Trust
No 5 G Indirect By the Michael D.Clayman 2006 Revocable Trust
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 24,600 Indirect By the Michael D. Clayman Irrevocable Trust
Common Stock 388,683 Indirect By Versant Development Fund III, LLC
Footnotes
  1. The weighted average purchase price for the transaction reported was $17.0953, and the range of prices were between $16.95 and $17.33. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
  2. Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares.